The concern of generic challenges has consistently loomed above copyright’s famous drug, PDE5 Inhibitor, triggering questions about the future of connected medicinal stakes. While initial years saw impressive gains, the exclusivity end has opened the way for cheaper alternatives, likely lowering profitability and posing a real risk for stakeholde